Prognostic value of Isocitrate Dehydrogenase mutations in myelodysplastic syndromes: A retrospective cohort study and meta-analysis

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Jin, Jie ^a,b   Hu, Chao ^a,b   Yu, Mengxia ^a,b   Chen, Feifei ^a,b   Ye, Li ^a,b   Yin, Xiufeng ^a,b   Zhuang, Zhengping ^c   Tong, Hongyan ^a,b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; ANTINEOPLASTIC AGENT; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ARTICLE; DATA ANALYSIS; DISEASE ACTIVITY; GENE; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; ISOCITRATE DEHYDROGENASE GENE; META ANALYSIS; MOLECULAR PATHOLOGY; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; SEQUENCE ANALYSIS; SOMATIC MUTATION; SURVIVAL RATE; ADOLESCENT; ADULT; AGED; FEMALE; FOLLOW UP; GENETICS; MALE; MIDDLE AGED; MORTALITY; MUTATION; MYELODYSPLASTIC SYNDROMES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84903269633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0100206     Document Type: Article

References (50)

1. Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, et al. (2007) Myelodysplastic syndromes: the complexity of stem-cell diseases. Nat Rev Cancer 7: 118-129. (Pubitemid 46164747)
2. Nimer SD (2008) Myelodysplastic syndromes. Blood 111: 4841-4851.
3. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, et al. (2011) Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496-2506.
4. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89: 2079-2088. (Pubitemid 27132124)
5. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, et al. (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120: 2454-2465.
6. Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, et al. (2007) Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 25: 3503-3510. (Pubitemid 47315575)
7. Bejar R, Levine R, Ebert BL (2011) Unraveling the molecular pathophysiology of myelodysplastic syndromes. J Clin Oncol 29: 504-515.
8. Shih AH, Levine RL (2011) Molecular biology of myelodysplastic syndromes. Semin Oncol 38: 613-620.
9. Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, et al. (2008) A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22: 538-543. (Pubitemid 351386723)
10. Reitman ZJ, Yan H (2010) Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst 102: 932-941.
11. Chung YR, Schatoff E, Abdel-Wahab O (2012) Epigenetic alterations in hematopoietic malignancies. Int J Hematol 96: 413-427.
12. Kaelin WG Jr (2011) Cancer and altered metabolism: potential importance of hypoxia-inducible factor and 2-oxoglutarate-dependent dioxygenases. Cold Spring Harb Symp Quant Biol 76: 335-345.
13. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100: 2292-2302.
14. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, et al. (2012) Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients. Leukemia 26: 101-105.
15. Thol F, Weissinger EM, Krauter J, Wagner K, Damm F, et al. (2010) IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica 95: 1668-1674.
16. Lin J, Yao DM, Qian J, Chen Q, Qian W, et al. (2012) IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 91: 519-525.
17. Lin TL, Nagata Y, Kao HW, Sanada M, Okuno Y, et al. (2013) Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica.
18. Lin CC, Hou HA, Chou WC, Kuo YY, Liu CY, et al. (2013) IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Am J Hematol.
19. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8: 16.
20. Tong H, Hu C, Yin X, Yu M, Yang J, et al. (2013) A Meta-Analysis of the Relationship between Cigarette Smoking and Incidence of Myelodysplastic Syndromes. PLoS One 8: e67537.
21. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50: 1088-1101.
22. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634. (Pubitemid 27387172)
23. Bennett JM (2000) World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72: 131-133.
24. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, et al. (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189-199. (Pubitemid 12073508)
25. Tothova Z, Steensma DP, Ebert BL (2013) New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res 19: 1637-1643.
26. Muto T, Sashida G, Oshima M, Wendt GR, Mochizuki-Kashio M, et al. (2013) Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders. J Exp Med 210: 2627-2639.
27. Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I, et al. (2011) Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One 6: e19868.
28. Jin G, Reitman ZJ, Spasojevic I, Batinic-Haberle I, Yang J, et al. (2011) 2- hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations. PLoS One 6: e16812.
29. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274. (Pubitemid 44571966)
30. Yoshida K, Sanada M, Kato M, Kawahata R, Matsubara A, et al. (2011) A nonsense mutation of IDH1 in myelodysplastic syndromes and related disorders. Leukemia 25: 184-186.
31. Rocquain J, Carbuccia N, Trouplin V, Raynaud S, Murati A, et al. (2010) Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias. BMC Cancer 10: 401.
32. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, et al. (2010) Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24: 1094-1096.
33. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, et al. (2010) Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood 116: 2122-2126.
34. Pardanani A, Lasho TL, Finke CM, Mai M, McClure RF, et al. (2010) IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24: 1146-1151.
35. Tefferi A, Jimma T, Sulai NH, Lasho TL, Finke CM, et al. (2012) IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia 26: 475-480.
36. Chou WC, Lei WC, Ko BS, Hou HA, Chen CY, et al. (2011) The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia. Leukemia 25: 246-253.
37. Chou WC, Hou HA, Chen CY, Tang JL, Yao M, et al. (2010) Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 115: 2749-2754.
38. Caramazza D, Lasho TL, Finke CM, Gangat N, Dingli D, et al. (2010) IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia. Leukemia 24: 2120-2122.
39. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, et al. (2012) Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 120: 4649-4652.
40. Dinardo CD, Propert KJ, Loren AW, Paietta E, Sun Z, et al. (2013) Serum 2- hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. Blood 121: 4917-4924.
41. Steensma DP (2006) Are myelodysplastic syndromes "cancer"? Unexpected adverse consequences of linguistic ambiguity. Leuk Res 30: 1227-1233.
42. Khan H, Vale C, Bhagat T, Verma A (2013) Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol 50: 16-37.
43. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462: 739-744.
44. Figueroa ME, Abdel-Wahab O, Lu C, Ward PS, Patel J, et al. (2010) Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18: 553-567.
45. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD, et al. (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17: 225-234.
46. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, et al. (2009) Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha. Science 324: 261-265.
47. Tong H, Hu C, Zhuang Z, Wang L, Jin J (2012) Hypoxia-inducible factor-1alpha expression indicates poor prognosis in myelodysplastic syndromes. Leuk Lymphoma 53: 2412-2418.
48. Head DR, Jacobberger JW, Mosse C, Jagasia M, Dupont W, et al. (2011) Innovative analyses support a role for DNA damage and an aberrant cell cycle in myelodysplastic syndrome pathogenesis. Bone Marrow Res 2011: 950934.
49. Grimes DA, Schulz KF (2002) Cohort studies: marching towards outcomes. Lancet 359: 341-345. (Pubitemid 34119302)
50. Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, et al. (2012) ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22: 180-193.